← Back to headlines
FDA approves Immuneering therapy for second-line metastatic pancreatic cancer
The biotech firm highlighted the regulatory milestone while reiterating its strategic focus on developing treatments for first-line patients in future trials.
26 Aug, 21:16 — 26 Aug, 21:16
